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Calcium Phosphates (CaPs) have excellent bone regeneration capacity, and their 
combination with specific drugs is of interest because it allows adding new 
functionalities. In CaPs, drug release is mainly driven by diffusion, which is strongly 
affected by the porosity of the matrix and the drug-material interaction. Therefore, it is 
very difficult to tune their drug release properties beyond their intrinsic properties. 
Furthermore, when the CaPs are  designed as scaffolds, the increased complexity of the 
macrostructure further complicates the issue.  
This work investigates for the first time the use of biocompatible plasma-polymers to 
provide a tool to control drug release from drug-loaded CaP scaffolds with complex 
surfaces and intricate 3D structure. Two different CaPs were selected displaying great 
differences in microstructure: low-temperature CaPs (Calcium-deficient hydroxyapatite 
cements, CDHA) and sintered CaP ceramics (β-Tricalcium Phosphate, β-TCP). The 
deposition of PCL-co-PEG (1:4) copolymers on CaPs was achieved by a low pressure 
plasma process, which allowed coating the inner regions of the scaffolds up to a certain 
depth. The coating covered the micro and nanopores of the CaPs surface and produced 
complex geometries presenting a nano and micro rough morphology which lead to low 
wettability despite the hydrophilicity of the copolymer.  Plasma coating with PCL-co-
PEG on scaffolds loaded with Simvastatin acid (potentially osteogenic and angiogenic) 
allowed delaying and modulating the drug release from the bone scaffolds depending on 
the thickness of the layer deposited, which, in turn depends on the initial specific 






Calcium Phosphates (CaP) are excellent candidates in bone replacement due to their 
similarity to the mineral phase of bone and potential resorbability [1, 2]. Their 
combination with different types of drugs allows providing them with additional 
functionalities, in addition to their excellent osteoconductivity and osteogenicity.  
However, in CaPs a part of the loaded drug often remains trapped in the matrix [3, 
4]. This could be partly solved by introduction of macroporosity to the material, by 
production of different kinds of scaffolds [5,6]. In any case – both in bulk materials 
as in scaffolds - the performance of these ceramic matrices as drug delivery systems 
is tightly linked to their inherent porosity and pore size distribution features, which 
is dependent on the fabrication method followed [3]. Thus, whereas biomimetic 
calcium phosphate cements exhibit a high porosity, ranging from the nanometric to 
the micrometric scale, the porosity in sintered CaP ceramics tends to be micrometric 
in size.  
Thus, a common problem is that drug release cannot be tuned beyond their intrinsic 
capacity, which is related with their porosity. Therein, adapting the release profile to 
specific pathologies requiring a certain rate of delivery poses a problem. Coating of 
the material’s surface could be a solution. However, once the ceramic matrices are 
loaded with drugs, coating by conventional wet methods can lead to loss of drug 
from the material to the coating media.  
In those cases, a promising novel approach to tune the drug release kinetics can be 
found in low temperature plasma technologies. Low temperature plasma, herein 
plasma, can be defined as a particular state of a gas or mixture of gases containing a 
mixture of ions, free radicals, electrons, excited molecules, UV and visible radiation 
that preserves electrical neutrality. This reactive medium can modify the first 
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nanometers of the surface of the material without altering its bulk properties. 
Roughly, the three main effects of plasmas on the surface of a material are: i) 
functionalization or grafting (covalent bonding of new chemical species); ii) etching 
(removal of surface material); and iii) thin film deposition (deposition of thin 
layers).  
These effects may be employed to tailor drug release; Recent works [7,8] have 
shown that surface functionalization of polyamide 6.6 fibres can improve the 
amount of anti-inflammatories and lipolithic agents released due to improved 
interaction of the materials with the surrounding media.  
Another approach which can be used to slow down the drug release profile is by 
creation of thin films by plasma polymerisation on the surface of the materials, 
acting as barrier for its release. Coating by plasma polymerization refers to the 
deposition of polymer films due to the excitation of an organic monomer in the gas 
state and subsequent deposition and polymerization of the excited species on the 
surface of a substrate [9]. 
Few works have investigated plasma polymerization to produce an overlayer to 
control the release kinetics of drugs placed on the surface of solid carrier surfaces. 
Vasilev et al. have coated Vancomycin contained in nanoporous anodic aluminium 
oxide with allyllamine plasma layers [10]. In another work, quartz surfaces were 
employed as supports for a first n-heptylamine plasma polymer layer, to allow 
suitable wettability of Levofloxacin which was subsequently coated with a second 
n-heptylamine layer [11]. Similarly, quartz surfaces were employed as supports for 
model dye molecules (Methylene Blue) or anticancer agents (Cisplatin) and were 
plasma coated with multilayered biodegradable Poly caprolactone-co-
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polyethyleneglycol (PCL-co-PEG) coatings [12]. Both authors have shown that by 
gradually increasing the barrier layer thickness with plasma polymerization 
deposition time, the amount of drug released diminished. In all cases, simple model 
surfaces have been employed.  
However, coating of complex surfaces in 3D scaffold structures and being able to 
fine tune drug release from them is far from being obvious. Therefore, it is the main 
aim of this work to show the potential of plasma polymerization in drug modulation 
from complex ceramic scaffolds for bone regenerative applications. These scaffolds 
were obtained by foaming of a calcium phosphate cement, and contained different 
levels of micro and nanoporosity, depending on the subsequent treatment applied, 
namely low-temperature setting to yield Calcium Deficient Hydroxyapatite (CDHA) 
or high-temperature sintering to produce E-Tricalcium Phosphate (E-TCP). Given 
the great differences on the surface texture of both ceramic materials, in the first 
stage, we investigated the deposition of biocompatible PCL-co-PEG polymer layers 
on 2D discs. Subsequently, the level of complexity was increased introducing 3D 
scaffolds, and the coating of the surface and the penetration of the plasma-polymers 
within the scaffolds was ascertained. To evaluate the possibilities of these layers on 
drug release, Simvastatin acid (SVA), was incorporated to the CaP scaffolds. In 
local drug delivery to the bone site from CaPs, different drugs are of interest [3]. 
SVA has shown potential action on bone and blood vessel formation [13-14], which 
is of clear interest in views of improving bone healing. Thus, to tailor the SVA 
release from the scaffolds plasma polymerisation of a biocompatible and 
biodegradable copolymer of PCL-co-PEG was evaluated as barrier layer in different 
conditions, and its potential effect on modulating the drug release kinetics was 





HCaprolactone (HCL, Purity: 97%, MW: 114, Empirical formula: C6H10O2), and the 
cyclic esther monomer Diethylene glycol dimethyl ether (DEGME, Purity: 99.5%, MW: 
134.17, linear formula: (CH3OCH2CH2)2O) were purchased from Sigma Aldrich, 
France and used in this study without further purifications. Simvastatin (≥97%, 
MW:418.57, Sigma-Aldrich) was used as the precursor of Simvastatin acid (SVA), 
which was prepared according to [15]. 
(1) 
D-TCP was used as starting material for the preparation of the powder phase of the 
cement, and was obtained by heating in a furnace (Hobersal CNR-58) in air, an 
appropriate mixture of calcium hydrogen phosphate (CaHPO4, Sigma Aldrich) and 
calcium carbonate (CaCO3, Sigma-Aldrich) at 1400ºC for 15 h followed by quenching 
in air. D-TCP powder was milled in an agate ball mill (Pulverisette 6, Fritsch GmbH) 
with 10 balls (d=30mm) for 15 min at 450 rpm and blended with 2%wt of precipitated 
hydroxyapatite (PHA)(HA; BP-E341, Merck, Germany), which was added as a seed. 
The liquid phase employed in the preparation of cements consisted of a 2.5% solution of 
Na2HPO4 (Panreac) in MilliQ water, while the liquid phase used to prepare scaffolds 
was a solution of 1 wt% of Polysorbate 80, herein Tween80 (Polysorbate 80, Sigma 
Aldrich, USA) in distilled water. 10 wt% Pluronic F-127 (Sigma Aldrich, USA) was 




2.2. Preparation of low temperature and sintered CaP ceramic discs and scaffolds 
CaP discs were used for the characterization of the polymer layer obtained. In the first 
place, CaP cements were prepared with a liquid-to-powder (L/P) ratio of 0.35 mL/g. 
The powder phase was mixed with the liquid phase in a mortar for about 1 min and then 
transferred into disc moulds of 2 x 15 mm. Samples were allowed to set in Ringer’s 
solution (0.9 % NaCl) for 7 days to obtain Calcium-Deficient Hydroxyapatite (CDHA) 
discs.  
To obtain E-Tricalcium Phosphate (E-TCP) ceramic discs, the CDHA samples were 
sintered in an oven (Hobersal), in air, by heating for 2.5 h up to 400ºC, and then for 
2.20h up to 110ºC where samples were maintained for 9 h. Cooling was achieved 
naturally.  
Calcium phosphate scaffolds were prepared by foaming, using a L/P ratio of 0.55 mL/g. 
The powder phase was a mixture of D-TCP containing 2 wt% of PHA and 10 wt% 
Pluronic F-127. The liquid phase was a solution of 1%wt of Tween80 in water. The 
foams were injected into moulds (6 mm diameter x 12 mm height) and allowed to set as 
described. To obtain E-TCP scaffolds, the CDHA scaffolds were sintered applying the 
same protocol used for the E-TCP ceramic discs. 
2.3.Methods 
2.3.1. Plasma polymerization of PCL-co-PEG coatings 
PCL-co-PEG coatings were fabricated in a low pressure inductively excited radio 
frequency-tubular quartz plasma reactor system (5 cm diameter, 40 cm length, base 
pressure of 3x10-2 mbar). The schematics of plasma deposition setup and technical 
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details of the process have been provided in earlier works [12, 16, 17]. Briefly, the 
partial pressure ratio of the two monomers fed in the reactor was controlled by the flow 
rate of carrier gas (i.e. Ar, Air liquide, France), which was regulated and measured by 
electronic mass flow controllers (MKS instruments). The partial pressure in the reactor 
of HCL and DEGME exhibited linear correlations with the flow rate of argon gas and 
were comparable with each other [12]. Plasma co-polymerization of organic monomers 
was carried out on CDHA and E-TCP discs for the preliminary study on the layer 
characteristics, as well as on SVA-loaded macroporous CDHA and E-TCP scaffolds. 
For the current study, the total flow rate was varied from 20 to 25 standard cubic 
centimeter per minute (SCCM) by keeping the operating pressure constant at 0.5 mbar. 
Two operating modes were investigated to deposit the plasma coatings: Continuous 
Wave (CW) or Pulse Wave (PW).  
Copolymer coatings were deposited at 20W CW plasma for 20 min or 90 min followed 
by deposition of a copolymer in a 1W PW plasma for 5 min to improve the surface 
wettability. The pulsed plasma discharge coatings were performed for 20 min, the peak 
power (Ppk) was 25W and the duty cycle (DC = (ton / (ton+toff), where ton and toff were the 
‘plasma ON’ and ‘plasma OFF’ times respectively) was 4% to obtain the effective 
plasma power (Peff) which was 1W PW (ton = 4 ms and toff = 96 ms). After polymer 
deposition, the reactor was again evacuated to base pressure before the plasma 








2.3.2. Characterization of Plasma Polymerized Coatings 
X-ray Photoelectron Spectroscopy 
The chemical composition was analyzed by XPS with a SPECS (Germany) using an Al 
non monocromatic source XR50 (200W and 14 kV) with an analyzer Phoibos 150 
MCD-9 with pass energy of 25eV, high resolution steps of 0.1eV, chamber pressure of 
5.109 mbar and using a Flood gun FG15/40. Peak deconvolution was performed with 
CasaXPS software.  
Surface Wettability Measurements 
Sessile drop contact angle values were measured using a video capture apparatus 
(Digidrop GBX-3S system, France). For each measurement, 6 PL of DI water droplets 
were dispensed onto the coated surfaces. Four measurements were carried out on each 
coating and resulting values were averaged.  
Scanning Electron Microscopy 
Surface topography of CDHA and E-TCP discs was studied by Field-Emission 
Scanning Electron Microscopy using a Jeol JSM-5000/5610 SEM. Samples were Pd-Pt-
coated before SEM observation. Observations were carried out at 10 kV working 
voltage. 
Focus Ion Beam 
To ascertain the thickness of the plasma polymer layer deposited on the CDHA and E-
TCP surface, Focus Ion Beam tomography (FIB, Zeiss Neon40) was performed. A 30 x 





The Specific Surface Area (SSA) of the CaPs was measured by Nitrogen adsorption 
according to the Brunauer-Emmet-Teller (BET) method, (BET) in an ASAP 2020 
(Micromeritics). 
Mercury intrusion porosimetry 
 
Mercury Intrusion Porosimetry (MIP, AutoPore IV, Micromeritics, USA) was 




CaP scaffolds were loaded with SVA by immersion in 200 Pg SVA/ml solution (1 
mL/cylinder) during 2 h in the case of CDHA or 24 h in the case of E-TCP to achieve 
equilibration maximum impregnation. The CaP scaffolds were subsequently freeze-
dried.  
Drug release experiments 
CDHA and E-TCP scaffolds loaded with SVA and plasma-coated as described were 
immersed in 3 ml of Phosphate Buffer Saline (PBS, pH=7.4) at 37ºC with continuous 
stirring. 350 μL of sample was withdrawn at different time points and replaced by 350 
μL of fresh PBS. 
The amount of drug released was obtained by measuring the release media collected at 
each time point by High performance liquid chromatography (HPLC) in a Shimadzu 
HPLC system. A mobile phase of Acetonitrile: 0.1% Phosphoric acid at a ratio of 50:50 
(v/v), at a flow rate of 0.8 ml/min was passed through a C8 column (Shim-pack, 
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Shimadzu). An injection volume of 10 Pl of the release sample was measured by 
photodiode array (PDA) at Omax = 238 nm.  
Results 
Characterization of the plasma polymer layer 
In this work two CaP materials were employed: CDHA obtained by low-temperature 
setting of a calcium phosphate cement, and E-TCP ceramic, obtained by sintering the 
former at high temperature. Both kinds of materials were subjected to low temperature 
plasma polymerization of a biocompatible and biodegradable copolymer mixture of 
PCL-co-PEG 1:4. As shown in Fig. 1 a) and b) the microstructure of the two substrates 
was significantly different, just as the SSA, which was much higher for CDHA 
(SSACDHA = 20m2/g) than for E-TCP (SSAβ-TCP= 0.60m2/g). The scanning electron 
micrographs obtained on the surface of the materials (Fig. 1) revealed the typical 
microporous structure of E-TCP with its sintering grains, while CDHA consisted of 
entangled platelet-like crystals derived from the dissolution-precipitation responsible for 
cement hardening.   
In the first place it was of interest to characterize the plasma polymer layer deposited 
with CW discharge on the two materials at the longest time evaluated of 90 min.  
FTIR measurements were performed on material obtained from the top surface of the 
CaPs. All materials tested display phosphate vibrations (Supplementary material 1), 
where the wide, strong bands correspond to Q3 stretching (944–1122 cpom-1) and Q4 
bending (545–640 cm-1) typical of calcium phosphates or apatites [18, 19]. On the 
plasma coated materials, E-TCP-90CW and CDHA-90CW, different bands indicated the 
presence of the coating, which were more evident in E-TCP-90CW. In particular, bands 
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were recorded at 1716 cm-1, which were attributed to the C=O stretching vibrations of 
the ester carbonyl group from PCL; C-H stretching bonds were centered at 2950 and 
2870 cm-1. The C-H bending was observed at 1380 and 1460 cm-1. The weak absorption 
band at 3430 cm-1 was assigned to terminal -OH groups in the coatings which indicated 
the presence of polar groups incorporated into the copolymer structures [12], as -OH 
groups from hydroxyapatite usually appear at higher bending energies 3567 cm-1 [20].  
 
Modifications on the surface energy and surface chemistry were recorded by means of 
static contact angle and XPS measurements, respectively (Table 1). Both untreated 
materials were very hydrophilic and due to their inherent porosity absorbed water very 
fast, not allowing contact angle measurement. However, after plasma polymerization 
water was no longer absorbed and the contact angle rose to hydrophobic values above 
110° in both materials, showing the highest values for E-TCP-90CW. 
The surface chemistry of the untreated CaPs as measured by XPS correlated adequately 
with their nominal composition. The polymerization treatment with PCL-co-PEG led to 
a decrease in the O/C ratio, showing the presence of polymer on the surface. The layer 
deposited in the case of E-TCP-90CW was thicker than the detection limit of the XPS 
(10 nm), as Ca and P species were no longer detected by the technique. In the case of 
CDHA-90CW both Ca and P were detected but in very small quantities which could 
indicate that the CDHA is not completely covered by the plasma polymer. However, 
such low values measured can be also ascribed to background noise, so these particular 
Ca and P values presented in Table 1 should be taken with precaution.  
Decomposition of C1s core level spectra of the plasma polymerized samples (Table 2, 
Figure 2) showed a profile clearly including 3 peaks corresponding to: C-C and/or C-H 
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285.00 eV, which were the most abundant groups, followed by C-O at 286.63 eV (in 
ether  groups) and C=O 288.63 eV (probably carboxylic/ester groups). The presence of 
these bonds reflected the presence of the copolymer PCL: PEG 1:4. The contribution of 
the C=O peaks was slightly lower in E-TCP than in CDHA, in both cases up to around 
6%.   
As displayed in the SEM images (Figure 1), after plasma polymerization with PCL-co-
PEG the structure of the CaPs was covered by a layer following the original patterns of 
the materials, forming bush-like structures on E-TCP-90CW and worm-like structures 
for CDHA-90CW.  
Transversal sections obtained by FIB revealed that, as anticipated by XPS 
measurements, the plasma polymer deposited on E-TCP-90CW was thicker (1496 ± 
162nm) than that deposited on CDHA-90CW (628 ± 61 nm), in the same experimental 
conditions. 
Once demonstrated that it was possible to produce PCL-co-PEG coatings on the surface 
of flat CDHA and E-TCP discs, the possibility to obtain polymer layers on the surface 
of 3D macroporous samples, herein designated as CaP scaffolds, was assessed. As 
shown in the transversal section of a CaP scaffold (Figure 3 left), both E-TCP and 
CDHA scaffolds contained macropores of 80 Pm of pore entrance size (Figure 4), with 
a smaller volume of pores around 2 Pm corresponding to the distance between sintering 
necks / crystal aggregates. The plateau at the nanoscale range is only present in CDHA 
scaffolds and corresponds to intercrystal distance. The total porosity was of 81.5% for 
E-TCP and of 82.2% for CDHA. Plasma polymerization for 90CW min showed the 
same bush-like and worm-like structures in the pores located at the top surface of the 
samples (Figure 3, right). In addition, it was observed that for E-TCP, the plasma 
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process evaluated here was capable of depositing PCL-co-PEG coatings up to a depth of 
550 mm by diffusion through the interconnected macropores of the material. This was 
not visible for CDHA samples, where the coating was restricted to the outer surface.  
Drug loading and release 
CaP Scaffolds were drug-loaded by immersion in a solution containing SVA. SVA 
showed high affinity for CDHA as high loadings of 168 μg/scaffold were obtained in 
only two hours (Table 3), which accounts for 84 ± 6% loading efficiency. As E-TCP 
scaffolds displayed lower affinity they were allowed 24 h to equilibrate in the SVA 
solutions. Anyhow, the loading efficiency was much lower (9 ± 2 %) so the quantity of 
drug loaded in E-TCP was of 18.78 Pg.  
The drug release pattern for the SVA-loaded E-TCP and CDHA either untreated or after 
90 min of CW plasma coating is shown in Figure 5. Despite these loading diferences, 
the amount of drug released was very similar between the untreated E-TCP and CDHA 
scaffolds.  Over nearly 2 weeks (284 h) both untreated materials showed a progressive 
release, while the coated samples dislayed different behavior: E-TCP-SVA-90CW did 
not show any drug release along 2 weeks of experiment, while in the case of CDHA 
release was initially blocked, delayed for the first 2 h, and release progressed slowly 
afterwards.  
Once it was established that the plasma coatings were effective in blocking drug 
release, shorter treatment times and pulsed mode depositions were evaluated. All 
conditions evaluated completely blocked SVA release from E-TCP scaffolds. On 
the contrary, CDHA scaffolds coated with shorter polymerization times of 20 min 
in continuous wave mode (Fig. 6 a) displayed controlled release properties over the 
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course of the experiment. Plasma polymers produced in pulsed wave mode showed 
to be more efficiently blocking the surface in 20 min than CW polymers (Fig. 6 b), 
as release was delayed for 5 h and progressed slowly afterwards.  
Discussion 
To overcome the intrinsic limitations of CaPs to regulate drug release, this paper 
focuses on the use of biocompatible plasma-polymers to provide a tool to control drug 
release from drug-loaded CaP scaffolds with very complex surfaces and intricate 3D 
structures. One advantage of using a dry method such as plasma lies in avoiding, for 
instance, any ion dissolution of the calcium phosphates and thus conserving intact their 
initial properties. If the material has already been loaded with drugs, coating them is a 
complicated issue, as any contact with processing solutions would lead to 
dissolution/diffusion of the drugs and thus loss active principle from the biomaterial.  
In this work, it has been shown that plasma polymers (PCL-co-PEG) can be deposited 
on the surface of CaP cements and ceramics with very different surface features. As 
shown by the IR spectra (Figure 1), the bands corresponding to C-H, C-O and OH 
confirm the formation of a polymer layer on the surface of the ceramics. The thickness 
of this polymer layer is variable depending on the material used, i.e.  E-TCP ceramics or 
CDHA cements which have different morphologies and specific surface area (SSA). 
This was confirmed both by XPS (Table 1), in which the Ca and P species were not 
detectable – or hardly -  after the CW plasma polymerization treatment for 90 min, and 
also by SEM-FIB (Figure 2), which allowed measuring the thickness of the layers. 
Thus, E-TCP showed a layer which was two times thicker than the one deposited on 
CDHA in the same conditions. This can be attributed to the great differences in SSA 
between both materials (CDHA has 33 times higher SSA than E-TCP), which is related 
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to their structure, consisting in CDHA platelet-like crystals in one case, and flat porous 
structures typical of sintered materials in E-TCP.  The thickness of the layer obtained by 
CW plasma discharge for 90 min was much larger than that recorded in previous works 
[12], mainly due to the longer treatment times employed. The thickness of the coating 
(1.49 ± 0.16 and 0.63± 0.06 Pm on E-TCP and CDHA respectively) led to important 
changes in the surface topography of the CaP materials, leading to the formation of bush 
or worm-like structures. This change in surface morphology, together with the change 
in the chemical nature of the surface is expected to result in significant changes in the in 
vitro and in vivo biological performance of the material [9], which will have to be 
further investigated.  
The chemical structure of E-TCP and CDHA is Ca3(PO4)2, and Ca9(HPO4)(PO4)5(OH)2 
respectively, with a theoretical Ca/P ratio of 1.5 for both compounds [21]. None of the 
materials itself contains carbon, so its presence on the surface of the samples (Table 1) 
indicates an alteration of the surface chemistry, which could be ascribed to 
contamination by adsorbed hydrocarbons. The PCL-co- PEG 1:4 plasma coatings (90 
CW) deposited on the surface had a 0.3 O/C ratio in both E-TCP and CDHA, which was 
close to that of Bhatt et al. [9] (0.36 O/C), who employed different deposition 
conditions (mainly treatment time and substrates employed) (Table 1). Moreover, the 
coatings led to a significant change in the wetting properties of the materials; both CaPs 
were initially hydrophilic, with fast water absorption through the pores of the materials. 
After plasma polymerization these relatively low O/C ratios, together with blocking of 
the surface porosity, raised the surface hydrophobicity of the materials, which displayed 
contact angles between 115° and 121°. The high roughness of the materials, generated 
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in the growth of the plasma polymer on the intricate crystalline structures of the CaPs 
must also be related to these considerable differences in the wettability measurements. 
In the second part of the work, 3D CaP scaffolds made of E-TCP or CDHA were 
studied. These are the macroporous counterparts of the E-TCP and CDHA evaluated in 
the first part of the work, thus preserving their microstructure (Figure 1 a and b) but 
with additional interconnected macroporosity (Figure 3 left). The advantage of 
introducing macroporosity to CaPs is envisaged as a method to facilitate bone ingrowth 
not only from the external surface but throughout the bulk of the material [22]. This 
would accelerate its resorption and transformation into newly formed bone tissue [23]. 
It has also been shown that macroporosity is relevant for drug delivery, as it allows 
improving fluid flow throughout the material [5]. 
In the 3D treatment of the macroporous CaP scaffolds it was shown here that the plasma 
polymer coating can be performed successfully on the materials, and that the 
interconnections between the macropores allow the penetration of the plasma polymer 
inside the scaffold (Figure 3). This is particularly evident in the case of E-TCP, where 
the characteristic bush-like structures can be observed both on the surface, and inside 
pores of the scaffold down to a depth of 550 Pm (Figure 3).  The higher SSA of CDHA 
was probably related to the fact that the coating layer was restricted to the top surface of 
the CaP scaffolds, and no penetration was observed by SEM, as possibly all available 
monomer was already consumed in the coating of the wider surface. 
In the subsequent steps, the drug release of the plasma-coated scaffolds was evaluated. 
Simvastatin acid (SVA) was incorporated to the CaP scaffolds. Simvastatin is a 
commonly used cholesterol-lowering drug which has been shown to stimulate 
osteogenesis locally through an up-regulation of BMP-2 expression [24] and it has also 
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been related to dose-dependent improved angiogenesis [25]. Enhancing blood vessel 
growth within the scaffolds is of interest with views on promoting scaffold resorption 
and bone regeneration. 
The adsorption of SVA, which is a hydrophilic drug (Eq. 1), was much favoured in 
CDHA scaffolds than in E-TCP (table 3). This is reflected in drug loading of E-TCP 
being only 11% of that of CDHA – even after E-TCP samples allowed to equilibrate 
with the loading solution for 24 h in comparison to 2 h for CDHA scaffolds. As both 
kinds of scaffolds have very close porosity around 82%, this difference can probably be 
attributed to the higher SSA of CDHA but also to its different chemistry, which can 
probably allow for the creation of hydrogen bonds with SVA.  
Drug release patterns were significantly modified by the PCL-co-PEG plasma coatings 
deposited (Figs. 5 and 6). On the one hand, uncoated E-TCP scaffolds showed a 
continuous progressive release for the first 5 h where 98% of the initial drug loads was 
released. After 3 days the drug in the media started degrading (shown by a decrease of 
the measured drug in the media) (Fig. 5a). None of the E-TCP scaffolds plasma coated 
with the PCL-co-PEG in different conditions showed any SVA release in the evaluated 
timeframe of 11 days (Data not shown - Scheme shown in Fig. 5a). This is indicative of 
the lack of diffusion of SVA through the thick plasma layer deposited on the E-TCP, 
shown to be much thicker than that of CDHA in the 90 CW coated samples. It is 
important to recall that the amount of SVA loaded into E-TCP is an order of magnitude 
lower than that of CDHA, so even thinner coatings of 20CW (Supplementary material 
2) are able to block release from E-TCP.  
In contrast, untreated CDHA scaffolds showed continuous release for more than 10 
days, although the amount released was only around 16 % of the initial SVA loading 
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(Fig. 5b). The 90 CW PCL-co-PEG layer on the drug-loaded CDHA scaffolds was three 
times thinner than that of E-TCP. Initially (first 1.5h) it blocked SVA release and 
subsequently allowed its slow diffusion along the timeframe of the experiment. Shorter 
treatment times of 20 min (CDHA-SVA-20CW) presented the same profile (Fig. 6a), 
and though release started from the beginning of the experiment, the rate of release was 
slowed down with respect to the untreated CDHA scaffolds. This is in agreement with a 
previous work, where Bhatt et al. [12] showed that by gradually increasing the barrier 
layer thickness with longer plasma deposition times, the amount of a dye released was 
reduced.  
 
In parallel, the mode of deposition clearly affected the drug release, as only 20 min of 
treatment in pulsed mode (CDHA-SVA-20PW) were able to block the release for the 
initial 5 h, allowing afterwards for sustained release (Fig. 6b).  This is most probably 
related to a lower extent of monomer fragmentation achieved by pulsed discharges, with 
higher retention of ether functional groups [26, 27]. Plasma phase fragmentation plays 
an important role in determining the deposition rate and surface chemistry of the 
deposited film and depends on the kind of monomer [28].  
The drug delivery matrices developed in this work constitute complex structures, which 
combine: i) a highly porous (macro, micro and nanoporous) non-degrading bulk [3] 
which was shown to release drugs (ie. antibiotics) through complex mechanisms 
following non-Fickian diffusion [5] with ii) a biodegradable plasma polymer coating. 
The mechanisms involved in drug release from this kind of coatings on flat surfaces 
were shown to range from zero-order to non-Fickian diffusion as the coating thickness 
increased [12].  Thus, the drug release in the developed dosage forms is expected to be 
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ruled by the coating until it is completely degraded, followed by diffusion from the CaP 
matrix afterwards.  
 
Conclusions 
This work has allowed demonstrating that it is possible to fine-tune drug release from 
3D ceramic scaffolds (CDHA & E-TCP) with different and very complex surface 
textures by a dry plasma polymerization process by employing biocompatible plasma 
polymers, depending on the treatment conditions. The thickness and structure of the 
PCL-co-PEG (1:4) polymer layer obtained is highly dependent on the texture of the 
materials, in particular on its SSA.  Thicknesses of up to 1.4 Pm were obtained on E-
TCP, and the plasma polymers were able to penetrate the macroporous structure of 3D 
calcium phosphate foams, up to a certain depth. The topography and chemistry of the 
materials were significantly modified by the coatings which led to nano-rough 
structures which could explain the low wettability measured on the materials.   
Simvastatin acid (SVA) was incorporated to the calcium phosphate scaffolds of E-TCP 
and CDHA as osteogenic and angiogenic drug, and the plasma coatings were useful to 
modulate the drug release: thicker PCL-co-PEG layers acted as barriers on E-TCP 
foams impairing SVA release throughout the whole release experiment (11 days), while 
on CDHA the presence of thinner polymer layers – due to its much higher SSA - 
allowed for the diffusion of the drug, leading to progressive and controlled drug release 
with respect to the uncoated biomaterial. On CDHA, longer treatment times (90 min in 
continuous wave plasma discharges) implied initially blocking of release followed by a 
slow release pattern, while shorter times (20 min) allowed a slow, controlled release. 
Pulsed wave plasma discharges allowed efficiently depositing plasma polymer layers 
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which could initially block the release, in shorter times (20 min). Thus, the plasma 
coatings evaluated have shown to be useful tools for the tuning of drug release from 
bone biomaterials, allowing to produce ceramic dosage forms combining delayed 
release, followed by controlled delivery of drugs.  
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Table 1. Static contact angle and X-ray photoelectron spectroscopy (atomic 
concentration and atomic ratio) of the different CaP discs either untreated of after 
plasma polymerization 
 Ts (º) Atomic concentration % Atomic ratio  C1s O1s Ca2p P2p O/C Ca/P 
β-TCP * 14.83 53.61 19.54 11.98 3.61 1.63 
β-TCP-90CW 121 ± 2 76.99 23.01 -- -- 0.29 -- 
CDHA * 10.51 57.81 19.05 12.62 5.50 1.51 
CDHA-90CW 115 ± 1 76.09 23.75 0.12** 0.04** 0.30 --** 
*Not possible to measure contact angle due to too fast water absorption.  


















Table 2. C1s peak deconvolution 
 
 Atomic percentage 
 C1s 






E-TCP-90CW 55.7 37.9 6.4 
























Table 3. Simvastatin acid loaded and final amount released (11 days) from CDHA and 
E-TCP scaffolds with different plasma polymerization times.  
Samples Qloaded (Pg) Qreleased (Pg)  
E-TCP-SVA 18.8 ± 3.7 18.4 ± 0.4 
E-TCP-SVA-20CW 18.8 ± 3.7 0.0 ± 0.0 
E-TCP-SVA-90CW 18.8 ± 3.7 0.1 ± 0.1 
E-TCP-SVA-20PW 18.8 ± 3.7 1.3 ± 0.1 
CDHA-SVA 168.1 ± 12.9 27.6 ± 11.7 
CDHA-SVA-20CW 168.1 ± 12.9 2.5 ± 2.5 
CDHA-SVA-90CW 168.1 ± 12.9 4.7 ± 0.7 








































Figure 1. SEM images of the different materials before (top images) and after plasma 
polymerization with PCL-PEG (4:1). β-TCP (a), β-TCP-90CW (b), CDHA (c) and 
CDHA-90CW  (d) and FIB-SEM cross-section of the surface of both polymerized 
materials (e) β-TCP-90CW and (f) CDHA-90CW. 
 
Figure 2. X-ray Photoelectron Spectroscopy C1s peak deconvolution, of (a) E-TCP and 
(b) CDHA with PCL-co-PEG (1:4) plasma coating 90CW.  
 
Figure 3. Scanning electron micrographs of transversal sections of E-TCP and CDHA 
scaffolds after 90 min CW plasma polymerization at different depths. Views of the 
surface of pores found on the top surface layer (top image), at a depth of 550 Pm, and 
at 1500 Pm (lower image).  
 
Figure 4. Pore entrance size distribution of E-TCP and CDHA obtained by Mercury 
Intrusion Porosimetry.   
 
Figure 5. Cumulative release of SVA in (%) from E-TCP (a) or CDHA (b) scaffolds 
either untreated of after 90 min coating in continuous wave mode with hypothesis on the 
possible phenomena taking place (below).  
 
Figure 6. Release pattern for SVA from CDHA scaffolds at (a) different treatment times 
with continuous wave  mode (CW) or (b) different power supply mode being either 
continous (CW) or pulsed (PW).  
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